Xpert MTB/RIF and Xpert Ultra assays for pulmonary tuberculosis and rifampicin resistance in adults irrespective of signs or symptoms of pulmonary tuberculosis

Objectives
\nThis is a protocol for a Cochrane Review (diagnostic). The objectives are as follows:
\n
\nTo determine the accuracy of Xpert MTB/RIF and Xpert Ultra for screening for tuberculosis in adults irrespective of signs or symptoms of pulmonary tuberculosis in the general population (i.e. low‐risk population).
\n
\nTo determine the accuracy of Xpert MTB/RIF and Xpert Ultra for screening of pulmonary tuberculosis in adults in the following high‐risk groups.
\n
\nPeople living with HIV.
\n
\nHousehold contacts of people with tuberculosis.
\n
\nPatients residing in high‐tuberculosis‐burden settings attending primary health facilities.
\n
\nHomeless people.
\n
\nMiners.
\n
\nPeople with diabetes mellitus.
\n
\nPeople who abuse alcohol.
\n
\nSmokers.
\n
\nPeople residing in prisons.
\n
\nHealthcare workers.
\n
\nTo determine the accuracy of Xpert MTB/RIF and Xpert Ultra for the detection of rifampicin resistance in the general population and in the high‐risk groups and settings described above.
\n
\nSecondary objectives
\nTo compare the accuracy of Xpert MTB/RIF and Xpert Ultra in the above high‐risk groups and settings.
\n
\nTo investigate potential sources of heterogeneity in accuracy estimates, including the percentage of participants with tuberculosis symptoms, tuberculosis burden, tuberculosis/HIV burden, and MDR‐TB burden.